Suppr
超能文献

Nivolumab plus ipilimumab in advanced renal-cell carcinoma.

作者信息

Gunjur Ashray

出版信息

Lancet Oncol. 2018 May;19(5):e232. doi: 10.1016/S1470-2045(18)30257-2. Epub 2018 Mar 29.

DOI:10.1016/S1470-2045(18)30257-2

PMID:29606588

Abstract

摘要

相似文献

Nivolumab plus ipilimumab in advanced renal-cell carcinoma.

Lancet Oncol. 2018 May;19(5):e232. doi: 10.1016/S1470-2045(18)30257-2. Epub 2018 Mar 29.

NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma.

Lancet Oncol. 2019 Jul;20(7):904-905. doi: 10.1016/S1470-2045(19)30351-1. Epub 2019 May 15.

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.

Jpn J Clin Oncol. 2021 Apr 1;51(4):646-653. doi: 10.1093/jjco/hyaa229.

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.

Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.

Cancer Treat Res Commun. 2021;27:100349. doi: 10.1016/j.ctarc.2021.100349. Epub 2021 Mar 10.

Nivolumab plus ipilimumab in metastatic colorectal cancer.

Lancet Oncol. 2018 Mar;19(3):e139. doi: 10.1016/S1470-2045(18)30067-6. Epub 2018 Jan 26.

Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.

Int J Urol. 2023 Sep;30(9):714-721. doi: 10.1111/iju.15128. Epub 2022 Dec 21.

Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation.

Clin Genitourin Cancer. 2019 Aug;17(4):315-318. doi: 10.1016/j.clgc.2019.05.023. Epub 2019 May 25.

引用本文的文献

Association of mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.

Am J Cancer Res. 2022 Apr 15;12(4):1766-1783. eCollection 2022.

Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery.

Genomics Proteomics Bioinformatics. 2021 Apr;19(2):191-207. doi: 10.1016/j.gpb.2021.02.004. Epub 2021 May 14.

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade.

Front Oncol. 2021 Mar 11;11:617335. doi: 10.3389/fonc.2021.617335. eCollection 2021.

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.

J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001696.

CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC).

Cancer Cell Int. 2020 Oct 27;20:519. doi: 10.1186/s12935-020-01603-2. eCollection 2020.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.

Ann Oncol. 2019 Jan 1;30(1):44-56. doi: 10.1093/annonc/mdy495.

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.

Respir Res. 2018 Oct 5;19(1):197. doi: 10.1186/s12931-018-0885-x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Nivolumab plus ipilimumab in advanced renal-cell carcinoma.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译